Bridgeway Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Bridgeway Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.24M	Hold	330,019	–	–	0.02%	661
2025 Q4	$993K	Sell	330,019 -63,300	-16%	-$160K	0.02%	706
2025 Q3	$747K	Sell	393,319 -50,000	-11%	-$87.2K	0.02%	740
2025 Q2	$630K	Buy	443,319 +154,600	+54%	+$209K	0.01%	735
2025 Q1	$442K	Buy	288,719 +7,600	+3%	+$16.2K	0.01%	765
2024 Q4	$697K	Buy	281,119 +82,000	+41%	+$204K	0.02%	745
2024 Q3	$229K	Buy	199,119 +48,419	+32%	+$59.4K	0.01%	1034
2024 Q2	$166K	Buy	+150,700	New	+$177K	﹤0.01%	1090
2021 Q3	–	Sell	-135,000	Closed	-$2.37M	–	1284
2021 Q2	$2.37M	Sell	135,000 -79,300	-37%	-$1.8M	0.04%	558
2021 Q1	$5.4M	Sell	214,300 -25,100	-10%	-$491K	0.1%	274
2020 Q4	$1.55M	Sell	239,400 -35,000	-13%	-$148K	0.03%	611
2020 Q3	$705K	Hold	274,400	–	–	0.02%	781
2020 Q2	$445K	Buy	+274,400	New	+$368K	0.01%	893
2020 Q1	–	Sell	-87,500	Closed	-$165K	–	1270
2019 Q4	$165K	Hold	87,500	–	–	﹤0.01%	1217
2019 Q3	$95K	Hold	87,500	–	–	﹤0.01%	1248
2019 Q2	$192K	Buy	+87,500	New	+$477K	﹤0.01%	1189

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bridgeway Capital Management's ACRS Position: Q1 2026 in Review

Bridgeway Capital Management held its Aclaris Therapeutics (ACRS) position steady in Q1 2026 at 330,019 shares worth $1.24M. The position accounts for 0.02% of the portfolio, ranked #661.

Bridgeway Capital Management first reported a position in ACRS in Q2 2019 and has held it in 16 quarters since. The position peaked at $5.4M in Q1 2021. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

Bridgeway Capital Management held 330,019 shares of Aclaris Therapeutics worth $1.24M as of Q1 2026.
Bridgeway Capital Management left its Aclaris Therapeutics share count unchanged in Q1 2026.
Aclaris Therapeutics made up 0.02% of Bridgeway Capital Management's portfolio in Q1 2026, its #661 holding.
Bridgeway Capital Management first reported a position in Aclaris Therapeutics in Q2 2019 and has held it in 16 quarters since.
Bridgeway Capital Management's Aclaris Therapeutics position peaked at $5.4M in Q1 2021.
136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.